

## **Touchlight signs license agreement with Voyager for use of Touchlight's DNA technology in Voyager's capsid discovery platform**

**Hampton, UK, 15 November 2022** – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids.

Under the license agreement, Voyager gains rights to Touchlight's DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager's pipeline and supporting Voyager alliances with leading biopharma partners.

Touchlight's enzymatically amplified doggybone DNA technology enables the rapid and scalable amplification of DNA regardless of sequence length or complexity and is being deployed across genetic medicine applications including mRNA, AAV, lentivirus, genome editing and DNA vaccines. doggybone DNA is amplified *in vitro*, avoiding the constraints of using cells for DNA amplification, thus also enabling applications such as the production of high-diversity DNA libraries.

**Karen Fallen, Group CEO of Touchlight, commented:** *"Today's announcement is another example of the power and breadth of application of the doggybone DNA platform. We're delighted that the platform is being utilised to contribute to the advancement of novel gene therapies for diseases of high unmet medical need."*

Financial terms are not disclosed.

**-ENDS-**

### **About Touchlight**

Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as [doggybone DNA](#) or dbDNA™.

dbDNA is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight's revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.



TOUCHLIGHT

Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, [Touchlight DNA Services](#).

Find out more at [www.touchlight.com](http://www.touchlight.com)

Follow Touchlight on [LinkedIn](#)

Follow @TouchlightDNA on [Twitter](#)

For more information please contact:

**Touchlight**

Robin Bodicoat, Head of Marketing

E: [info@touchlight.com](mailto:info@touchlight.com)

T: +44 20 8481 9200

**Instinctif Partners**

Agnes Stephens / Jonjo Cordey

E: [touchlight@instinctif.com](mailto:touchlight@instinctif.com)

T: +44 20 7457 2020